Nav: Home

Study: Does a cancer cell's shape hint at its danger?

October 19, 2016

Doctors can sometimes use a cancer cell's genetics to predict how it will act - how dangerous it is and thus what treatments should be used against it. Now a paper published in the journal Integrative Biology shows that a cancer cell's shape may offer similar clues. Eventually, the researchers from Colorado State University hope that their measurements of cell shape could be combined with genomic data to offer a more precise prognosis and guide strategies for treating a patient's disease.

"This is the tip of the iceberg - the beginning of an investigation taking shape - which comes from a well-known fact that the process of carcinogenesis leads to mis-regulation of the cytoskeleton. In other words, the formation of cancer changes the shape of cells," says Ashok Prasad, PhD, assistant professor in the CSU Department of Chemical & Biological Engineering.

He points out that when a pathologist examines a tumor sample, he or she may see physical abnormalities in a cell's growth or nucleus or chromosomes. However, "Our hypothesis is that there are subtler changes in shape at a statistical level, early in the process of carcinogenesis, that a computer could pick up," Prasad says.

To determine what these changes may be, Prasad and colleagues including first author Elaheh Alizadeh, PhD candidate in the Prasad lab, first had to quantify cell shape. Rather than trying to categorize cells as "a little oblong" or "somewhat spherical", the group used what are called Zernike moments to precisely capture cell dimensions. Basically, a Zernike moment, named after physicist Frits Zernike who won the 1953 Nobel Prize in Physics, is a way of representing shapes as data. This requires choosing a finite number of measurements (the researchers chose 256), which then became a sort of numerical cell-shape signature. The researchers also found a way to represent differences in Zernike moments between cell lines as vectors. The question was whether a vector describing differences in Zernike moments could help identify which cell line was likely to be the most invasive.

"Machine learning is a tool that you have to give some examples - you have to say 'these are oranges and these are apples' and then a neural network can learn what distinguishes one from the other. Then you give the system an apple and see if it can correctly tell you which one it is," Alizadeh says.

In this case, the "apples" and "oranges" were more and less invasive osteosarcoma cell lines.

"The four cell lines we used, the model can predict them with good accuracy," Alizadeh says. With an undergraduate degree in physics and a Masters in plasma engineering (both earned while studying in Tehran, Iran), and now PhD work in chemical engineering that includes machine learning, Alizadeh's background allows a unique perspective on this line of research that draws on all three, combining the physics of Zernike moments with the challenge of data mining with the realities of gathering data from human cell lines.

After proving the promise of their model, the question was what would happen when the team's machine learning confronted a hypothetical fifth cell line, as would be the case if asked to evaluate a new patient sample. "What we found is that if we first allowed our neural network to evaluate new cells - to recalibrate its categorization based on the characteristics of these new cells - it does predict the classes pretty well," Alizadeh says.

However, Prasad and Alizadeh point out that significant questions remain. For example, how a cell is prepared for imaging can affect its shape - "What you put these cells on when you look at them may affect what you see," Prasad says. Likewise, there are myriad ways to quantify cell shape, of which Zernike moment is only one possibility. Future research will explore additional ways to capture the data of a cell's dimensions.

Still, "If we could say that this set of shape changes represents these genetic changes - if we could do this, I think it would be amazing," Prasad says. "It would let us add shape as one more variable in determining a cancer's prognosis from biopsy."
-end-


University of Colorado Anschutz Medical Campus

Related Cancer Articles:

Radiotherapy for invasive breast cancer increases the risk of second primary lung cancer
East Asian female breast cancer patients receiving radiotherapy have a higher risk of developing second primary lung cancer.
Cancer genomics continued: Triple negative breast cancer and cancer immunotherapy
Continuing PLOS Medicine's special issue on cancer genomics, Christos Hatzis of Yale University, New Haven, Conn., USA and colleagues describe a new subtype of triple negative breast cancer that may be more amenable to treatment than other cases of this difficult-to-treat disease.
Metabolite that promotes cancer cell transformation and colorectal cancer spread identified
Osaka University researchers revealed that the metabolite D-2-hydroxyglurate (D-2HG) promotes epithelial-mesenchymal transition of colorectal cancer cells, leading them to develop features of lower adherence to neighboring cells, increased invasiveness, and greater likelihood of metastatic spread.
UH Cancer Center researcher finds new driver of an aggressive form of brain cancer
University of Hawai'i Cancer Center researchers have identified an essential driver of tumor cell invasion in glioblastoma, the most aggressive form of brain cancer that can occur at any age.
UH Cancer Center researchers develop algorithm to find precise cancer treatments
University of Hawai'i Cancer Center researchers developed a computational algorithm to analyze 'Big Data' obtained from tumor samples to better understand and treat cancer.
New analytical technology to quantify anti-cancer drugs inside cancer cells
University of Oklahoma researchers will apply a new analytical technology that could ultimately provide a powerful tool for improved treatment of cancer patients in Oklahoma and beyond.
Radiotherapy for lung cancer patients is linked to increased risk of non-cancer deaths
Researchers have found that treating patients who have early stage non-small cell lung cancer with a type of radiotherapy called stereotactic body radiation therapy is associated with a small but increased risk of death from causes other than cancer.
Cancer expert says public health and prevention measures are key to defeating cancer
Is investment in research to develop new treatments the best approach to controlling cancer?
UI Cancer Center, Governors State to address cancer disparities in south suburbs
The University of Illinois Cancer Center and Governors State University have received a joint four-year, $1.5 million grant from the National Cancer Institute to help both institutions conduct community-based research to reduce cancer-related health disparities in Chicago's south suburbs.
Leading cancer research organizations to host international cancer immunotherapy conference
The Cancer Research Institute, the Association for Cancer Immunotherapy, the European Academy of Tumor Immunology, and the American Association for Cancer Research will join forces to sponsor the first International Cancer Immunotherapy Conference at the Sheraton New York Times Square Hotel in New York, Sept.

Related Cancer Reading:

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Climate Crisis
There's no greater threat to humanity than climate change. What can we do to stop the worst consequences? This hour, TED speakers explore how we can save our planet and whether we can do it in time. Guests include climate activist Greta Thunberg, chemical engineer Jennifer Wilcox, research scientist Sean Davis, food innovator Bruce Friedrich, and psychologist Per Espen Stoknes.
Now Playing: Science for the People

#527 Honey I CRISPR'd the Kids
This week we're coming to you from Awesome Con in Washington, D.C. There, host Bethany Brookshire led a panel of three amazing guests to talk about the promise and perils of CRISPR, and what happens now that CRISPR babies have (maybe?) been born. Featuring science writer Tina Saey, molecular biologist Anne Simon, and bioethicist Alan Regenberg. A Nobel Prize winner argues banning CRISPR babies won’t work Geneticists push for a 5-year global ban on gene-edited babies A CRISPR spin-off causes unintended typos in DNA News of the first gene-edited babies ignited a firestorm The researcher who created CRISPR twins defends...